Track market-moving stories before they get noisy

California State Teachers Retirement System grew its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 49,331.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 282,654,735 shares of the medical research company’s stock after acquiring an additional 282,082,924 shares during the quarter. California State Teachers Retirement System owned about 76.44% of Thermo Fisher Scientific worth $141,711,778,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of the company. Legacy Wealth Managment LLC ID raised its stake in Thermo Fisher Scientific by 78.6% during the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 22 shares in the last quarter. Kilter Group LLC bought a new position in shares of Thermo Fisher Scientific in the second quarter worth $25,000. Allied Private Wealth LLC acquired a new position in shares of Thermo Fisher Scientific during the second quarter valued at $26,000. High Note Wealth LLC raised its stake in shares of Thermo Fisher Scientific by 170.6% during the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 29 shares in the last quarter. Finally, JPL Wealth Management LLC acquired a new stake in Thermo Fisher Scientific in the third quarter worth about $28,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Wall Street Analyst Weigh In Several equities analysts have commented on the stock. Evercore set a $570.00 target price on shares of Thermo Fisher Scientific in a research note on Monday, July 6th. HSBC upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 1st. Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Barclays increased their price target on Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an “overweight” rating in a research note on Friday, July 24th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $630.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, July 23rd. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $619.41.

Read Our Latest Research Report on TMO Insiders Place Their Bets In other news, VP Lisa P. Britt sold 11,440 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total value of $7,014,092.80. Following the transaction, the vice president directly owned 14,784 shares of the company’s stock, valued at $9,064,366.08. This trade represents a 43.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Joseph R. Holmes sold 420 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $584.81, for a total transaction of $245,620.20. Following the sale, the chief accounting officer owned 2,966 shares in the company, valued at $1,734,546.46. This represents a 12.40% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 73,768 shares of company stock worth $44,122,820 over the last three months. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Down 0.2% NYSE TMO opened at $612.75 on Monday. Thermo Fisher Scientific Inc. has a 12 month low of $435.27 and a 12 month high of $647.00. The company has a market capitalization of $226.56 billion, a P/E ratio of 32.96, a PEG ratio of 2.57 and a beta of 0.85. The company’s 50 day simple moving average is $570.91 and its 200 day simple moving average is $515.17. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. During the same quarter in the previous year, the business posted $4.28 earnings per share. The firm’s quarterly revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 25.13 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend The business also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.11%.

Thermo Fisher Scientific Company Profile (Free Report)

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Featured Stories Five stocks we like better than Thermo Fisher Scientific AI Token Costs Are Changing the Hardware vs. Software Debate 3 ETFs That Could Move as Rate Expectations Shift 3 Stocks With September Catalysts Investors Shouldn’t Ignore Ollie’s Bargain Outlet Stock Falls on Weak Comps Despite Margin Gains

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific today announced the launch of the Thermo Scientific™ Multiskan™ Ease Absorbance Microplate Reader, designed to support protein quantification, enzyme-linked immunosorbent assays (ELISAs), cell viability studies, microbial growth monitoring and other routine laboratory applications with simplified operation and dependable performance. Laboratories performing absorbance-based analysis are under increasing pressure to generate reliable data.

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today introduced the Thermo Scientific™ Orbitrap™ Isora™ Mass Spectrometer and Orbitrap Isora Pro Mass Spectrometer, the company's first Orbitrap instruments with a dedicated isotope ratio analysis mode. Together with the Thermo Scientific™ Vanquish™ Duo UHPLC System and new Isotope Discoverer™ Software, the instruments form an integrated workflow designed to make molecular-level isotope ratio analys.

Bank OZK purchased a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 2,186 shares of the medical research company’s stock, valued at approximately $1,096,000.

A number of other institutional investors and hedge funds have also recently made changes to their positions in TMO. North Dakota State Investment Board bought a new position in Thermo Fisher Scientific in the fourth quarter valued at about $7,505,000. BlackRock Inc. purchased a new stake in Thermo Fisher Scientific during the second quarter worth about $15,501,867,000. German American Bancorp Inc. purchased a new stake in Thermo Fisher Scientific during the second quarter valued at about $4,920,000. Hudson Value Partners LLC boosted its position in shares of Thermo Fisher Scientific by 24.9% in the second quarter. Hudson Value Partners LLC now owns 16,653 shares of the medical research company’s stock valued at $8,349,000 after acquiring an additional 3,317 shares during the period. Finally, Clearstead Trust LLC bought a new position in shares of Thermo Fisher Scientific during the 2nd quarter valued at about $3,779,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Key Headlines Impacting Thermo Fisher Scientific Here are the key news stories impacting Thermo Fisher Scientific this week:

Positive Sentiment: Thermo Fisher introduced the Thermo Scientific EMPAD G2 electron detector, designed to enable faster, high-speed four-dimensional scanning transmission electron microscopy. The product could support demand for the company’s analytical-instrument portfolio and strengthen its position in advanced materials research. Thermo Fisher Scientific Introduces the EMPAD G2 Electron Detector Positive Sentiment: A recent analysis examines whether Isora could provide Thermo Fisher with an additional long-term growth opportunity, potentially broadening the company’s exposure to emerging research and laboratory markets. Can Isora Unlock a New Growth Edge? Neutral Sentiment: Thermo Fisher’s latest reported quarter showed solid momentum: adjusted EPS of $6.03 exceeded estimates, revenue reached $11.99 billion, and sales increased 10.5% year over year. Fiscal 2026 EPS guidance remains $24.93-$25.33, but much of this strength may already be reflected in the stock’s elevated valuation. Neutral Sentiment: Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating, although the average price target of $619.41 is below recent trading levels. Several firms have raised targets toward $650, suggesting optimism but limited upside at the current valuation. Negative Sentiment: CEO Marc Casper sold 275 shares for approximately $172,000 after selling 10,000 shares worth about $6.3 million earlier in the month. Both transactions were executed under pre-arranged Rule 10b5-1 plans, reducing their significance as a signal of deteriorating fundamentals, but the sales can still weigh on sentiment. Analysts Set New Price Targets Several equities research analysts have weighed in on TMO shares. Wells Fargo & Company dropped their price objective on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Evercore set a $570.00 price target on shares of Thermo Fisher Scientific in a research report on Monday, July 6th. Jefferies Financial Group reiterated a “buy” rating and issued a $630.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, July 23rd. Wolfe Research initiated coverage on Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 price target on the stock. Finally, Stifel Nicolaus set a $650.00 target price on shares of Thermo Fisher Scientific in a research note on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $619.41. Get Our Latest Stock Analysis on Thermo Fisher Scientific

Insider Buying and Selling at Thermo Fisher Scientific In related news, CEO Marc N. Casper sold 275 shares of the business’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $627.05, for a total value of $172,438.75. Following the completion of the transaction, the chief executive officer owned 123,925 shares of the company’s stock, valued at approximately $77,707,171.25. The trade was a 0.22% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa P. Britt sold 11,440 shares of the stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the transaction, the vice president directly owned 14,784 shares in the company, valued at approximately $9,064,366.08. This represents a 43.62% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 73,768 shares of company stock worth $44,122,820 over the last ninety days. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Stock Down 0.5% NYSE TMO opened at $630.66 on Friday. The company has a market cap of $233.18 billion, a P/E ratio of 33.92, a P/E/G ratio of 2.58 and a beta of 0.85. The business has a fifty day moving average price of $555.52 and a 200 day moving average price of $511.31. Thermo Fisher Scientific Inc. has a one year low of $435.27 and a one year high of $647.00. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business had revenue of $11.99 billion during the quarter, compared to analysts’ expectations of $11.71 billion. During the same period in the prior year, the business posted $4.28 EPS. The company’s revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s payout ratio is 10.11%.

Thermo Fisher Scientific Company Profile (Free Report)

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Read More Five stocks we like better than Thermo Fisher Scientific Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape SEC Probe Puts Wall Street Leverage Risk Back in Focus A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole Five Below’s Turnaround Is Working—But Has the Stock Run Too Far? Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Beacon Pointe Advisors LLC purchased a new position in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund purchased 37,709 shares of the medical research company’s stock, valued at approximately $18,906,000.

Several other hedge funds also recently modified their holdings of the business. Legacy Wealth Managment LLC ID raised its holdings in Thermo Fisher Scientific by 78.6% in the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 22 shares in the last quarter. Kilter Group LLC bought a new stake in shares of Thermo Fisher Scientific during the second quarter valued at approximately $25,000. Allied Private Wealth LLC acquired a new position in shares of Thermo Fisher Scientific in the second quarter valued at $26,000. High Note Wealth LLC lifted its position in Thermo Fisher Scientific by 170.6% in the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after purchasing an additional 29 shares during the period. Finally, Swiss RE Ltd. acquired a new stake in Thermo Fisher Scientific during the fourth quarter worth $28,000. 89.23% of the stock is owned by institutional investors.

Analysts Set New Price Targets A number of equities analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Sanford C. Bernstein initiated coverage on shares of Thermo Fisher Scientific in a research note on Friday, June 26th. They set a “market perform” rating and a $520.00 price target for the company. HSBC lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating and lowered their price objective for the company from $670.00 to $540.00 in a research note on Wednesday, June 3rd. Morgan Stanley increased their target price on Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an “overweight” rating in a report on Friday, July 24th. Finally, Evercore set a $570.00 price target on Thermo Fisher Scientific in a research note on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $619.41.

Get Our Latest Research Report on TMO Insiders Place Their Bets In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 420 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $584.81, for a total transaction of $245,620.20. Following the sale, the chief accounting officer directly owned 2,966 shares in the company, valued at approximately $1,734,546.46. This trade represents a 12.40% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Marc N. Casper sold 275 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $627.05, for a total transaction of $172,438.75. Following the completion of the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at approximately $77,707,171.25. The trade was a 0.22% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 73,768 shares of company stock worth $44,122,820. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Stock Down 1.4% NYSE:TMO opened at $621.87 on Friday. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a 12-month low of $435.27 and a 12-month high of $647.00. The firm has a market capitalization of $229.94 billion, a P/E ratio of 33.45, a P/E/G ratio of 2.57 and a beta of 0.85. The stock’s fifty day simple moving average is $558.64 and its 200-day simple moving average is $512.08.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. The company had revenue of $11.99 billion during the quarter, compared to analysts’ expectations of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.Thermo Fisher Scientific’s revenue was up 10.5% on a year-over-year basis. During the same period in the prior year, the business posted $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be issued a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s payout ratio is 10.11%.

(Free Report)

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Read More Five stocks we like better than Thermo Fisher Scientific 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude? Okta Stock Surges 29%—Is $200 the Next Stop?

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Avanda Investment Management Pte. Ltd. acquired a new position in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 4,000 shares of the medical research company’s stock, valued at approximately $2,005,000. Thermo Fisher Scientific accounts for approximately 0.7% of Avanda Investment Management Pte. Ltd.’s investment portfolio, making the stock its 16th largest position.

Other large investors also recently modified their holdings of the company. J. Stern & Co. LLP grew its stake in shares of Thermo Fisher Scientific by 58,006.4% in the fourth quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company’s stock worth $18,258,082,000 after acquiring an additional 31,455,105 shares during the last quarter. BlackRock Inc. bought a new stake in shares of Thermo Fisher Scientific during the second quarter worth about $15,501,867,000. Norges Bank purchased a new stake in Thermo Fisher Scientific in the 4th quarter valued at $3,072,744,000. Bank of New York Mellon Corp purchased a new stake in Thermo Fisher Scientific in the 2nd quarter valued at about $1,974,561,000. Finally, Auto Owners Insurance Co raised its position in Thermo Fisher Scientific by 57,845.0% in the fourth quarter. Auto Owners Insurance Co now owns 2,427,896 shares of the medical research company’s stock worth $1,406,844,000 after acquiring an additional 2,423,706 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth Several brokerages have recently weighed in on TMO. Sanford C. Bernstein assumed coverage on Thermo Fisher Scientific in a research report on Friday, June 26th. They issued a “market perform” rating and a $520.00 price target for the company. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Robert W. Baird lowered their price target on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. HSBC downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating and dropped their price target for the stock from $670.00 to $540.00 in a research note on Wednesday, June 3rd. Finally, Jefferies Financial Group restated a “buy” rating and set a $630.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, July 23rd. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $619.41.

Check Out Our Latest Stock Analysis on Thermo Fisher Scientific Insider Buying and Selling In related news, VP Lisa P. Britt sold 11,440 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total value of $7,014,092.80. Following the sale, the vice president owned 14,784 shares of the company’s stock, valued at approximately $9,064,366.08. This represents a 43.62% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $565.00, for a total transaction of $226,000.00. Following the sale, the chief operating officer owned 24,651 shares in the company, valued at approximately $13,927,815. This trade represents a 1.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 63,493 shares of company stock valued at $37,657,681. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Price Performance TMO opened at $629.02 on Friday. The firm has a market cap of $232.58 billion, a price-to-earnings ratio of 33.84, a PEG ratio of 2.56 and a beta of 0.85. Thermo Fisher Scientific Inc. has a 12-month low of $435.27 and a 12-month high of $643.99. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. The stock’s 50-day moving average price is $542.53 and its 200 day moving average price is $509.70.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. The business had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same period in the previous year, the company posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a $0.47 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.11%.

Thermo Fisher Scientific Company Profile (Free Report)

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

See Also Five stocks we like better than Thermo Fisher Scientific Blueprint for a Boom: SEC Clears the Crypto Runway Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss Advance Auto Parts Plunged, But Its Turnaround Is Still Working Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates? Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Advisors Capital Management LLC purchased a new stake in shares of Thermo Fisher Scientific Inc. (NYSE: TMO) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 66,082 shares of the medical research company's stock, valued at approximately

BOK Financial Private Wealth Inc. purchased a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 3,366 shares of the medical research company’s stock, valued at approximately $1,689,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. North Dakota State Investment Board bought a new position in Thermo Fisher Scientific in the fourth quarter valued at about $7,505,000. BlackRock Inc. bought a new position in Thermo Fisher Scientific during the 2nd quarter worth approximately $15,501,867,000. Hudson Value Partners LLC lifted its holdings in Thermo Fisher Scientific by 24.9% in the second quarter. Hudson Value Partners LLC now owns 16,653 shares of the medical research company’s stock valued at $8,349,000 after buying an additional 3,317 shares during the period. Boston Trust Walden Corp boosted its position in shares of Thermo Fisher Scientific by 9.7% during the 4th quarter. Boston Trust Walden Corp now owns 43,973 shares of the medical research company’s stock valued at $25,480,000 after purchasing an additional 3,873 shares in the last quarter. Finally, Xponance LLC grew its position in shares of Thermo Fisher Scientific by 8.1% during the 4th quarter. Xponance LLC now owns 59,295 shares of the medical research company’s stock worth $34,358,000 after buying an additional 4,436 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes Several analysts have recently commented on the company. Wolfe Research started coverage on Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 target price for the company. Robert W. Baird decreased their price objective on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. Evercore set a $570.00 price objective on shares of Thermo Fisher Scientific in a research report on Monday, July 6th. Piper Sandler lifted their price objective on Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a “neutral” rating in a report on Monday, July 27th. Finally, Morgan Stanley boosted their target price on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an “overweight” rating in a report on Friday, July 24th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $619.41.

View Our Latest Analysis on Thermo Fisher Scientific Thermo Fisher Scientific Trading Up 4.3% NYSE TMO opened at $614.32 on Thursday. The company has a market capitalization of $227.14 billion, a price-to-earnings ratio of 33.05, a PEG ratio of 2.40 and a beta of 0.85. The stock’s 50-day simple moving average is $536.26 and its two-hundred day simple moving average is $508.51. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a twelve month low of $435.27 and a twelve month high of $643.99.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The business had revenue of $11.99 billion for the quarter, compared to analysts’ expectations of $11.71 billion. During the same period last year, the business earned $4.28 earnings per share. The business’s quarterly revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Research analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend The business also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.11%.

Insider Buying and Selling at Thermo Fisher Scientific In other news, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $565.00, for a total value of $226,000.00. Following the transaction, the chief operating officer owned 24,651 shares in the company, valued at approximately $13,927,815. This trade represents a 1.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa P. Britt sold 5,850 shares of Thermo Fisher Scientific stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $580.00, for a total transaction of $3,393,000.00. Following the completion of the transaction, the vice president directly owned 14,784 shares in the company, valued at approximately $8,574,720. The trade was a 28.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 52,053 shares of company stock worth $30,643,589 over the last quarter. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile (Free Report)

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Further Reading Five stocks we like better than Thermo Fisher Scientific Bloom Energy’s AI Surge Meets a Valuation Reality Check Target Is Winning Shoppers Back—Can the Rally Reach $180? IonQ’s Space Contract Points to a New Frontier for Quantum Investors Is Apple’s AI Strategy Smarter Than Skeptics Think?

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

BlackRock Inc. bought a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 30,919,632 shares of the medical research company’s stock, valued at approximately $15,501,867,000. BlackRock Inc. owned approximately 8.36% of Thermo Fisher Scientific as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of TMO. Pallas Capital Advisors LLC acquired a new position in shares of Thermo Fisher Scientific in the 2nd quarter worth $5,197,000. Deutsche Bank AG purchased a new position in shares of Thermo Fisher Scientific in the second quarter worth approximately $609,053,000. Perigon Wealth Management LLC purchased a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at approximately $13,385,000. Commerzbank Aktiengesellschaft FI purchased a new position in Thermo Fisher Scientific during the 2nd quarter worth approximately $32,967,000. Finally, Trust Co. of Vermont acquired a new stake in shares of Thermo Fisher Scientific in the second quarter worth $25,326,000. 89.23% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In A number of equities analysts have recently weighed in on the stock. Sanford C. Bernstein assumed coverage on shares of Thermo Fisher Scientific in a research note on Friday, June 26th. They issued a “market perform” rating and a $520.00 price target on the stock. Evercore set a $570.00 target price on shares of Thermo Fisher Scientific in a research note on Monday, July 6th. Weiss Ratings upgraded shares of Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, July 14th. Piper Sandler increased their target price on shares of Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a “neutral” rating in a research report on Monday, July 27th. Finally, Wells Fargo & Company decreased their price target on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $619.41.

View Our Latest Research Report on TMO Thermo Fisher Scientific Trading Up 0.8% Shares of NYSE:TMO opened at $590.00 on Wednesday. Thermo Fisher Scientific Inc. has a 52-week low of $435.27 and a 52-week high of $643.99. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. The company has a market cap of $218.15 billion, a P/E ratio of 31.74, a P/E/G ratio of 2.39 and a beta of 0.84. The stock’s 50-day moving average is $533.64 and its 200-day moving average is $508.36.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last released its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. During the same quarter last year, the firm posted $4.28 EPS. The company’s revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend The business also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be issued a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is 10.11%.

Insider Activity at Thermo Fisher Scientific In related news, CAO Joseph R. Holmes sold 420 shares of the business’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $584.81, for a total transaction of $245,620.20. Following the transaction, the chief accounting officer directly owned 2,966 shares in the company, valued at $1,734,546.46. The trade was a 12.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Lisa P. Britt sold 5,850 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $580.00, for a total value of $3,393,000.00. Following the completion of the sale, the vice president owned 14,784 shares of the company’s stock, valued at $8,574,720. This represents a 28.35% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 52,053 shares of company stock worth $30,643,589. Insiders own 0.33% of the company’s stock.

(Free Report)

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Read More Five stocks we like better than Thermo Fisher Scientific The AI Boom Is Turning This Cable Maker Into a Stock to Watch A Star Investor Just Trimmed Amazon—Here’s What It means Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look Home Depot Analysts See a Path to $375 and Beyond Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Avalon Trust Co purchased a new position in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 35,466 shares of the medical research company’s stock, valued at approximately $17,781,000. Thermo Fisher Scientific comprises 1.1% of Avalon Trust Co’s portfolio, making the stock its 27th biggest holding.

A number of other institutional investors and hedge funds have also recently bought and sold shares of TMO. North Dakota State Investment Board bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth about $7,505,000. Boston Trust Walden Corp lifted its holdings in Thermo Fisher Scientific by 9.7% in the 4th quarter. Boston Trust Walden Corp now owns 43,973 shares of the medical research company’s stock worth $25,480,000 after purchasing an additional 3,873 shares during the last quarter. Hudson Value Partners LLC boosted its position in Thermo Fisher Scientific by 24.9% during the second quarter. Hudson Value Partners LLC now owns 16,653 shares of the medical research company’s stock worth $8,349,000 after purchasing an additional 3,317 shares during the period. Xponance LLC grew its holdings in Thermo Fisher Scientific by 8.1% during the fourth quarter. Xponance LLC now owns 59,295 shares of the medical research company’s stock valued at $34,358,000 after purchasing an additional 4,436 shares during the last quarter. Finally, Annex Advisory Services LLC raised its position in shares of Thermo Fisher Scientific by 12.6% in the second quarter. Annex Advisory Services LLC now owns 24,656 shares of the medical research company’s stock valued at $12,361,000 after purchasing an additional 2,756 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insiders Place Their Bets In other news, VP Lisa P. Britt sold 5,850 shares of the stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $580.00, for a total value of $3,393,000.00. Following the completion of the transaction, the vice president directly owned 14,784 shares of the company’s stock, valued at approximately $8,574,720. This represents a 28.35% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Monday, July 27th. The shares were sold at an average price of $565.00, for a total value of $226,000.00. Following the transaction, the chief operating officer directly owned 24,651 shares of the company’s stock, valued at approximately $13,927,815. The trade was a 1.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 52,053 shares of company stock valued at $30,643,589 over the last 90 days. Company insiders own 0.33% of the company’s stock.

Analysts Set New Price Targets Several brokerages recently commented on TMO. Royal Bank Of Canada lifted their target price on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a “sector perform” rating in a report on Friday, July 24th. Barclays raised their price target on Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an “overweight” rating in a research report on Friday, July 24th. Robert W. Baird cut their price objective on Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. Wolfe Research assumed coverage on Thermo Fisher Scientific in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 target price on the stock. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $630.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, July 23rd. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $619.41. Read Our Latest Stock Report on TMO

Thermo Fisher Scientific Price Performance Shares of NYSE:TMO opened at $586.62 on Tuesday. The business’s 50 day moving average is $531.72 and its 200-day moving average is $508.48. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. The firm has a market capitalization of $216.90 billion, a PE ratio of 31.56, a PEG ratio of 2.39 and a beta of 0.84. Thermo Fisher Scientific Inc. has a 1-year low of $435.27 and a 1-year high of $643.99.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last issued its earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm had revenue of $11.99 billion during the quarter, compared to analysts’ expectations of $11.71 billion. During the same period last year, the business earned $4.28 earnings per share. Thermo Fisher Scientific’s quarterly revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s payout ratio is 10.11%.

(Free Report)

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Read More Five stocks we like better than Thermo Fisher Scientific Commodities Are Booming, But These 3 ETFs Tell Different Stories 3 Active ETFs Making Big Moves in August This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem Birkenstock Beats the Skeptics—But Not on EPS Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Diversified Trust Co. raised its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 71.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 17,214 shares of the medical research company’s stock after buying an additional 7,155 shares during the quarter. Diversified Trust Co.’s holdings in Thermo Fisher Scientific were worth $8,630,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Vanguard Group Inc. lifted its position in Thermo Fisher Scientific by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 34,133,702 shares of the medical research company’s stock valued at $19,778,774,000 after purchasing an additional 288,296 shares during the last quarter. J. Stern & Co. LLP increased its holdings in shares of Thermo Fisher Scientific by 58,006.4% in the 4th quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company’s stock worth $18,258,082,000 after buying an additional 31,455,105 shares during the last quarter. State Street Corp raised its position in shares of Thermo Fisher Scientific by 1.4% during the 4th quarter. State Street Corp now owns 16,613,761 shares of the medical research company’s stock valued at $9,633,991,000 after buying an additional 229,630 shares in the last quarter. Capital World Investors lifted its holdings in shares of Thermo Fisher Scientific by 7.0% during the 4th quarter. Capital World Investors now owns 11,003,814 shares of the medical research company’s stock worth $6,376,229,000 after acquiring an additional 718,669 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in Thermo Fisher Scientific by 0.3% in the fourth quarter. Geode Capital Management LLC now owns 8,196,477 shares of the medical research company’s stock worth $4,728,129,000 after acquiring an additional 26,425 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Down 0.0% Shares of NYSE:TMO opened at $588.17 on Monday. The stock has a market capitalization of $217.48 billion, a P/E ratio of 31.64, a price-to-earnings-growth ratio of 2.39 and a beta of 0.84. The stock’s 50-day moving average price is $529.37 and its 200-day moving average price is $508.75. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a 12-month low of $435.27 and a 12-month high of $643.99.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last released its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. The company had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.Thermo Fisher Scientific’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is 10.11%.

Analysts Set New Price Targets A number of equities research analysts have weighed in on TMO shares. Jefferies Financial Group restated a “buy” rating and set a $630.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, July 23rd. Stifel Nicolaus set a $650.00 price objective on Thermo Fisher Scientific in a research report on Wednesday, August 5th. Wells Fargo & Company decreased their price objective on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Royal Bank Of Canada upped their target price on Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a “sector perform” rating in a research note on Friday, July 24th. Finally, KeyCorp reiterated an “overweight” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, May 26th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $619.41.

Get Our Latest Report on TMO

Insider Transactions at Thermo Fisher Scientific In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $574.47, for a total value of $5,744,700.00. Following the transaction, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at $71,191,194.75. The trade was a 7.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph R. Holmes sold 420 shares of the company’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $584.81, for a total transaction of $245,620.20. Following the sale, the chief accounting officer owned 2,966 shares of the company’s stock, valued at $1,734,546.46. This represents a 12.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 52,053 shares of company stock valued at $30,643,589. 0.33% of the stock is currently owned by insiders.

About Thermo Fisher Scientific (Free Report)

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Further Reading Five stocks we like better than Thermo Fisher Scientific The Metals Company’s Big Bet Now Comes Down to a License OneSpaWorld Keeps Turning Cruise Demand Into Record Earnings Meta and Tesla Are Rebounding From Oversold Levels—Now What? AMG’s Alternatives Boom Powers Record Growth

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Bridgewater Advisors Inc. bought a new stake in shares of Thermo Fisher Scientific Inc. (NYSE: TMO) during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 2,380 shares of the medical research company's stock, valued at approximately $1,366,000. Other institutional investors also

Bryn Mawr Trust Advisors LLC purchased a new stake in shares of Thermo Fisher Scientific Inc. (NYSE: TMO) during the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 4,936 shares of the medical research company's stock, valued at approximately $2,475,000. Other hedge funds also

LUXEMBOURG & NEW YORK & PARIS--(BUSINESS WIRE)--Astorg, a leading pan-European private equity firm, today announced the successful completion of its acquisition of the global microbiology business from Thermo Fisher Scientific. The business will now operate as an independent company under the leadership of Chief Executive Officer Dirk Bontridder and will launch under a new corporate brand later in 2026. The Microbiology business is a global provider of diagnostic consumables and equipment used.

A sign marks the offices of Thermo Fisher Scientific offices in Waltham, Massachusetts, U.S., August 2, 2023. REUTERS/Brian Snyder/File Photo Purchase Licensing Rights, opens new tab

CompaniesHYDERABAD, Aug 10 (Reuters) - Thermo Fisher Scientific (TMO.N), opens new tab is eyeing a 15%-20% increase in its customer base in India over the next ​five years, betting on the growing biopharma research and ‌manufacturing ecosystem, the head of its India unit said.

The U.S.-based company, which makes lab and drug development equipment and supplies analytical instruments, antibodies, and genetic ​analysis products, said it is eyeing continued double-digit growth ​in India driven by rising demand from biopharma, semiconductor, and ⁠clean energy sectors.

Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.

"From a laboratory standpoint, as more laboratories create ​quality standards in line with global standards, our products will be ​found there. With more quality labs coming up, that's where our customer base is growing," Srinath Venkatesh, managing director for India and South Asia, told ​Reuters in an interview last week, but declined to disclose its ​current customer base.

The company is also counting on rising demand from the obesity-drug ‌market ⁠as more pharmaceutical companies in India work around the therapy area, he said.

Thermo Fisher serves customers globally, with the U.S. being its major market. The Asia-Pacific region accounts for about 18% of ​its revenue, with ​India among its ⁠fastest-growing markets, the company said.

"We expect continued double-digit CAGR (compound annual growth rate) growth from India. We ​have made deliberate investments in the region, more so ​than ⁠in the past," said Tony Acciarito, president for Asia Pacific, Middle East and Africa, who was also present in the interview.

The company employs ⁠more ​than 5,000 people in India and plans ​to expand its workforce, particularly in customer-facing roles, as it broadens its presence in ​the country, Venkatesh said.

Reporting by Rishika Sadam; Editing by Rashmi Aich

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Rishika leads Reuters’ coverage of India’s pharmaceutical and healthcare sector. Her reporting focuses on key themes such as the emergence of weight-loss drugs, the country’s drug regulatory framework and manufacturing quality standards, and developments shaping India’s pharmaceutical exports to major markets including the United States and Europe. She also covers the country’s rapidly growing hospital industry. With nearly a decade of experience in journalism, Rishika has previously reported extensively on Indian politics, national elections, and on social affairs and criminal justice.

Have you evaluated the performance of Thermo Fisher Scientific's (TMO - Free Report) international operations during the quarter that concluded in June 2026? Considering the extensive worldwide presence of this maker of scientific instrument and laboratory supplies, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth.

In the current era of a tightly interconnected global economy, the proficiency of a company to penetrate international markets significantly influences its financial health and trajectory of growth. For investors, the key is to grasp how reliant a company is on overseas markets, as this provides insights into the durability of its earnings, its ability to exploit different economic cycles, and its overall growth capabilities.

International market involvement serves as insurance against economic downturns at home and enables engagement with economies that are growing more quickly. Still, this move toward diversification is not without its challenges, as it involves navigating through the fluctuations of currencies, geopolitical threats, and the distinctive nature of various markets.

Our review of TMO's last quarterly performance uncovered some notable trends in the revenue contributions from its international markets, which are commonly analyzed and tracked by Wall Street experts.

The recent quarter saw the company's total revenue reaching $11.99 billion, marking an improvement of 10.5% from the prior-year quarter. Next, we'll examine the breakdown of TMO's revenue from abroad to comprehend the significance of its international presence.

Unveiling Trends in TMO's International RevenuesOther regions generated $430 million in revenues for the company in the last quarter, constituting 3.6% of the total. This represented a surprise of +16.76% compared to the $368.27 million projected by Wall Street analysts. Comparatively, in the previous quarter, Other regions accounted for $372 million (3.4%), and in the year-ago quarter, it contributed $383 million (3.5%) to the total revenue.

Of the total revenue, $2.1 billion came from Asia-Pacific during the last fiscal quarter, accounting for 17.5%. This represented a surprise of -1.87% as analysts had expected the region to contribute $2.14 billion to the total revenue. In comparison, the region contributed $1.97 billion, or 17.9%, and $1.92 billion, or 17.7%, to total revenue in the previous and year-ago quarters, respectively.

During the quarter, Europe contributed $3.31 billion in revenue, making up 27.6% of the total revenue. When compared to the consensus estimate of $3 billion, this meant a surprise of +10.46%. Looking back, Europe contributed $2.96 billion, or 26.9%, in the previous quarter, and $2.83 billion, or 26.1%, in the same quarter of the previous year.

Revenue Forecasts for the International MarketsWall Street analysts expect Thermo Fisher to report $11.91 billion in total revenue for the current fiscal quarter, indicating an increase of 7.1% from the year-ago quarter. Other regions, Asia-Pacific and Europe are expected to contribute 3.2% (translating to $376.78 million), 18.4% ($2.19 billion), and 25.7% ($3.07 billion) to the total revenue, respectively.

For the full year, the company is expected to generate $47.8 billion in total revenue, up 7.3% from the previous year. Revenues from Other regions, Asia-Pacific and Europe are expected to constitute 3.1% ($1.5 billion), 18.2% ($8.71 billion) and 25.5% ($12.17 billion) of the total, respectively.

The Bottom LineThe dependency of Thermo Fisher on global markets for its revenues presents a mix of potential gains and hazards. Thus, monitoring the trends in its overseas revenues can be a key indicator for predicting the firm's future performance.

In an era of growing international interdependencies and escalating geopolitical disputes, Wall Street analysts are vigilant in tracking these trends for businesses with a global reach, in order to refine their predictions of earnings. It should be noted, however, that a multitude of other elements, such as a company's domestic position, also play a significant role in shaping the earnings forecasts.

At Zacks, a company's changing earnings outlook is given considerable attention due to its proven, strong influence on a stock's price performance in the near term. The connection here is straightforward and positive: when earnings estimates are revised upward, the stock price generally follows suit, increasing as well.

The Zacks Rank, our proprietary stock rating tool, comes with an externally validated impressive track record. It effectively utilizes shifts in earnings projections to act as a dependable barometer for forecasting short-term stock price trends.

Currently, Thermo Fisher holds a Zacks Rank #3 (Hold), signifying its potential to match the overall market's performance in the forthcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

A Look at Thermo Fisher Scientific's Recent Stock Price PerformanceOver the past month, the stock has gained 9.7% versus the Zacks S&P 500 composite's 0.2% increase. The Zacks Medical sector, of which Thermo Fisher is a part, has risen 0.7% over the same period. The company's shares have increased 23.5% over the past three months compared to the S&P 500's 4.2% increase. Over the same period, the sector has risen 7.9%

Key Takeaways Thermo Fisher grew bioproduction with 3% organic Life Sciences Solutions growth and a filtration acquisition.TMO opened a U.S. Bioprocess Design Center to expand customer collaboration and process development.TMO added Clario's clinical data capabilities as integration and revenue-synergy efforts progressed. Thermo Fisher Scientific (TMO - Free Report) is building around three growth forces in life sciences: biologic-drug manufacturing, AI-enabled workflows and closer customer collaboration.

These themes can support longer-term expansion, but they also raise the bar. Thermo Fisher must keep launching relevant technologies, integrating acquisitions and proving that scale can translate into better execution.

Year to date, TMO shares have slipped 0.5%, compared with the industry's steeper 11.7% decline.

Image Source: Zacks Investment Research

TMO Expands Its Bioproduction PlatformBioproduction remained a key growth driver in the second quarter. Demand for tools and services used in biologic-drug development and manufacturing helped Life Sciences Solutions deliver 3% organic growth.

The Solventum filtration and separation acquisition broadens Thermo Fisher’s bioproduction offering across upstream and downstream workflows. Management expects the business to support revenue and cost synergies over time.

Thermo Fisher Brings AI Into WorkflowsThermo Fisher is expanding AI capabilities across its software portfolio. Those tools are designed to support smarter workflows and faster analysis in complex scientific applications.

The company is also applying AI within its PPI Business System. That matters because productivity, quality and customer responsiveness are becoming more important as laboratories handle larger datasets and more integrated workflows.

TMO Deepens Customer CollaborationThermo Fisher opened its flagship U.S. Bioprocess Design Center in Massachusetts during the quarter. The site expands its network of customer collaboration centers.

The center allows teams to work with pharma and biotech customers on process development, manufacturing optimization and commercial scale-up. TMO also announced a Singapore precision-health collaboration that combines Olink proteomics with the Orbitrap Astral platform.

Thermo Fisher Advances Clinical Data CapabilitiesThe Clario acquisition adds digital endpoint data solutions to Thermo Fisher’s portfolio. These capabilities can generate deeper clinical insights and improve drug-development productivity.

Clario also fits with Thermo Fisher’s clinical research business. The business exceeded management’s expectations in the second quarter, while integration remained on track and the revenue-synergy pipeline continued to grow.

TMO Innovation Must Outrun CompetitionCompetition remains a real constraint. Thermo Fisher operates in markets where technology changes quickly and customer requirements keep evolving.

Rivals can introduce alternative platforms, compete on pricing or bundle products and services more aggressively. That makes timely product launches, customer adoption and acquisition integration essential to sustaining share gains.

Danaher (DHR - Free Report) and Agilent Technologies (A - Free Report) remain relevant peers for investors watching innovation in life sciences tools, diagnostics and laboratory technologies. Danaher describes itself as a life sciences and diagnostics innovator, while Agilent supplies application-focused solutions across life sciences, diagnostics and applied chemical markets.

Thermo Fisher Momentum Supports the Trend StoryThe bottom line is that Thermo Fisher is aligned with attractive life-science trends, especially bioproduction, AI-led workflow improvement and clinical data capabilities. The case depends on execution as much as market demand.

Here’s how Thermo Fisher’s five-year sales multiple looks like compared to the industry average.

Image Source: Zacks Investment Research

TMO currently carries a Zacks Rank #3 (Hold). That indicates the long-term technology and demand themes have not yet translated into a stronger short-term rating.

The Momentum Score of A is encouraging because it points to favorable near-term trading characteristics. However, the Value Score, Growth Score and VGM Score of C call for measured expectations, especially after the stock’s recent earnings-driven support.

You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

All the firms we have covered on Wall Street for the past 15 years have lists of top stock ideas from their analyst pools. Some are just domestic stocks, some are European and Asian. Jefferies has a combined list that is called the Global Best Ideas list, described like this:

Jefferies’ Global Best Ideas list represents our highest-conviction, Buy-rated stocks across our Global Research Platform. These 24 top ideas are supported by differentiated analysis, bolstered by catalysts, and sit at valuation levels that suggest upside. Themes include: Secular Innovation & Capex, Structural Change, and Product Cycles & Pricing Power.

Five top Jefferies global picks are U.S. stocks that check a lot of boxes for what we believe is important now. The stock market is very overbought and expensive. Both the trailing and forward price-to-earnings readings for the S&P 500 are well above historical averages, and we are lined up for what could be a meaningful correction or even a bear market. All five make sense for growth and income investors looking for dependable passive income, and for some positive total return potential to keep pace with the current annual inflation rate of 3.5% for the 12 months ending in June, which was down from 4.2% in May. Core inflation, which excludes volatile food and energy prices, stands at 2.6% over the same period.

American Healthcare REIT With an aging U.S. population, this may be one of the best sectors to look at now, and the stock pays a 1.75% dividend. American Healthcare REIT (NYSE: AHR) is a self-managed real estate investment trust that acquires, owns, and operates a diversified portfolio of healthcare real estate properties, primarily senior housing, skilled nursing facilities, outpatient medical buildings, and other healthcare-related facilities.

The analysts at Jefferies said this:

American Healthcare REIT primarily owns private-pay senior housing, which it leases through a RIDEA structure that exposes it to the communities’ P&L. The current supply backdrop remains very positive for landlords, with active construction at multi-year lows and no signs of inflection. The demand backdrop is also very compelling for the senior housing sector. Based on OECD projections, the 80+ population is expected to grow at an average of +5.0% annually through 2030, well above the +1.8% CAGR from 2010 through 2025.

Its properties are in the United States, the United Kingdom, and the Isle of Man.

Its segments include:

Integrated senior health campuses OM, SHOP, and triple-net leased properties The OM buildings are leased to multiple tenants under separate leases. Its integrated senior health campuses each provide a range of independent living, assisted living, memory care, skilled nursing services, and ancillary businesses.

Its triple-net leased properties segment includes:

Senior housing Skilled nursing facilities Hospital investments The SHOP segment includes senior housing, which may provide:

Assisted living care Independent living Memory care Skilled nursing services Jefferies has a $65 price target for the shares.

Bank of America While Warren Buffett has trimmed his position over the past two years and sold a whopping 50 million shares in the fourth quarter of 2025, this quality financial giant remains an exceptional long-term holding, with a solid 1.83% dividend yield. Bank of America (NYSE: BAC | BAC Price Prediction) is a bank holding company that reported impressive Q2 results. Berkshire Hathaway owns 513,624,165 shares, which is 7.9% of the portfolio and 7.2% of the float. Berkshire did lower its Bank of America position in Q1 2026, but only modestly. According to the Q1 2026 13F filing, it was reduced by just 0.71%, a tiny cut compared to other positions.

Jefferies said this about the bank:

We view Bank of America as one of the most attractive opportunities among the large-cap banks, given its combination of durable earnings growth, improving capital markets activity, positive operating leverage, and significant capital return capacity. While investors often view BAC primarily through the lens of interest rates, we believe the company’s earnings outlook is supported by multiple drivers, including balance sheet growth, improving fee income, funding optimization, and fixed asset repricing. NT, we expect BAC to outperform its capital markets guidance, with investment banking and trading revenues tracking well above year-ago levels, while NII is trending toward the high end of management’s 6%-8% FY26 outlook.

Its segments include:

Consumer Banking offers a range of credit, banking, and investment products and services to consumers and small businesses. Global Wealth & Investment Management (GWIM) comprises two businesses: Merrill Wealth Management, which offers tailored solutions to meet clients’ needs through a comprehensive suite of investment management, brokerage, banking, and retirement products. Bank of America Private Bank provides comprehensive wealth management solutions. Global Banking offers a range of lending-related products and services, including integrated working capital management and treasury solutions, as well as underwriting and advisory services. Global Markets offers sales and trading services, as well as research services, to institutional clients across fixed income, credit, currency, commodity, and equity markets. The Jefferies target price for the shares is $75.

Caterpillar This is one of the best infrastructure ideas and will be a big winner in the massive construction and deployment of data centers, and it pays a reliable but modest 0.68% dividend. Caterpillar (NYSE: CAT) is a manufacturer of construction and mining equipment, off-highway diesel and natural gas engines, industrial gas turbines, and diesel-electric locomotives.

Jefferies said this about the company:

Caterpillar is highly levered to infrastructure build and commodity capacity expansion. Both are areas of the global economy that have been severely underinvested in over the last decade+. While most investors have been solely focused on CAT’s powergen business, which is benefiting from AI-driven data center infrastructure, reshoring, and megaprojects. We continue to believe that a large capital investment is needed globally to mine commodities to fuel the energy transition.

Its segments include:

Construction Industries Resource Industries Power & Energy Financial Products The Construction Industries segment is responsible for supporting customers using machinery in infrastructure and building construction applications. The Resource Industries segment develops and manufactures high-productivity equipment for both surface and underground mining operations worldwide. It also provides select work tools, machinery components, wear-and-maintenance components, and related parts.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Bank of America didn't make the cut. Grab the names FREE today.

The Power & Energy segment supports customers in oil and gas, power generation, marine, rail, and industrial applications, including Caterpillar machines. It also develops mining software solutions for the industry.

The company also provides financing and related services through its Financial Products segment.

Jefferies has a $1,045 price target for the blue chip giant.

Martin Marietta Materials With a positive backdrop for infrastructure growth across multiple levels, this stock is an outstanding idea with a small 0.60% dividend yield. Martin Marietta Materials (NYSE: MLM) is a supplier of aggregates and other building materials. The company operates through two segments: the East Group comprises the East and Southwest divisions. The West Group comprises the Central and West divisions.

Jefferies noted this:

The company has been dislocated from the broader heavy materials and building products peer group due to negative mix, which has impacted pricing. MLM announced a large deal to acquire Lhoist’s North American lime assets as a complement to its existing specialties portfolio, a market investors aren’t familiar with. Although 2026 will be noisy, we think this sets MLM up for a strong ’27+ on pricing as it will have carry-over from its mid-year increases, opportunity to raise prices at its recently acquired assets more than its heritage assets, and an easy comp due to unfavorable product mix.

The company provides magnesia and dolomitic lime products used globally in environmental, industrial, agricultural, and other specialty applications. It supplies aggregates (crushed stone, sand, and gravel) through its network of approximately 400 quarries, mines, and distribution yards in 28 states, Canada, and the Bahamas.

Martin Marietta Materials provides other building materials, namely, cement, ready-mixed concrete, asphalt, and paving services. The heavy-side building materials are used in infrastructure, nonresidential, and residential construction projects. Its aggregates are also used in agricultural, utility, and environmental applications, as well as railroad ballast.

Jefferies has a target price of $725 for the stock.

Thermo Fisher Scientific Perhaps off the radar for some, this stock only pays a small 0.15% dividend, but the upside potential is hard to ignore. Thermo Fisher Scientific (NYSE: TMO) is engaged in accelerating life sciences research, solving complex analytical challenges, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies.

Jefferies said this about the stock:

Our conviction in Thermo Fisher Scientific stems from a clear earnings inflection story, with organic growth stepping higher into 2H26 on the back of biopharma (60% of mix), where fundamentals remain strong across CRO, CDMO, and bioproduction. Notably, earnings continue to move higher despite muted near-term growth optics, reinforcing that the recent ~10% drawdown post 1Q results is multiple-driven rather than a deterioration in underlying earnings power.

Through its Life Sciences Solutions segment, it provides a portfolio of reagents, instruments, and consumables used in biological and medical research, the discovery and development of new drugs and vaccines, and the diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments and supporting consumables, software, and services for a range of applications.

The Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments, and associated products. The Laboratory Products and Biopharma Services segment offers virtually everything needed for the laboratory. It also provides purification and filtration technologies.

Jefferies has a $585 price objective.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Bank of America didn't make the cut. Grab the names FREE today.

Contact [email protected] for any questions or corrections.

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific today announced the global launch of Thermo Scientific™ InstaFlux™, an integrated media-on-demand enrichment workflow that helps food microbiology laboratories simplify media preparation, improve productivity and enhance sample traceability. Food testing laboratories face growing pressure to process more samples, meet turnaround expectations and maintain consistent quality while managing staffing constraints, sustainability goals and inc.

The life science giant’s quarterly sales of $11.994 billion increased 10% year-over-year, beating the analyst consensus estimate of $11.701 billion. Organic revenue growth was 5%.

Customer Activity Improves Across End MarketsIn an earnings conference call, the company noted good customer activity continues to strengthen across end markets during the second quarter.

Life Sciences Solutions sales increased 12.6% to $2.815 billion. Analytical Instruments sales were up 6.9% at $1.847 billion.

Specialty Diagnostics revenues reached $1.205 billion (+6.3%), and Laboratory Products and Biopharma Services sales were up 11.6% to $6.693 billion.

Pharma, Academic And Industrial Businesses Drive GrowthWithin pharma and biotech, Thermo Fisher delivered mid-single-digit growth in the second quarter, led by bioproduction and clinical research businesses, as well as the Research and Safety Market channel.

The academic and government segment grew low single digits in the second quarter, driven by the chromatography and mass spectrometry business.

The industrial and applied segment delivered mid-single-digit growth.

Thermo Fisher Raises 2026 Guidance"It’s great to see customer activity continue to strengthen across our end markets," said Marc Casper, Chairman and CEO.

"Our recently closed acquisitions are performing very well, and at the halfway point in the year we’re well positioned to deliver a great 2026."

Thermo Fisher Scientific raised its fiscal 2026 adjusted earnings per share guidance from $24.64-$25.12 to $24.93-$25.33 versus the consensus of $24.86.

The company increased its annual sales guidance from $47.3 billion-$48.1 billion to $47.40 billion-$48.10 billion compared to the consensus of $47.767 billion.

Thermo Fisher says expectations for 2026 revenue growth have increased to about 4%. It added that the guidance range remains 3%-4%, and now expects to deliver at the upper end of that range.

"We continue to have an active pipeline of M&A opportunities in our highly fragmented industry," Casper further added.

TMO Price Action: Thermo Fisher Scientific shares were up 9.05% at $574.09 at the time of publication on Thursday, according to Benzinga Pro data.

Photo: Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

23.7.2026 19:01

Index Dow Jones -0,92 % na 51739,82 b. S&P 500 -1,19 % na 7409,52 b. Nasdaq Composite -2,1 % na 25151,85 b.

Index Dow Jones odepisuje téměř procento pří výprodeji technologických společností. Mimo Alphabet klesá i Amazon (- 4,1 %) a Salesforce ( -3,5 %). Z indexu S&P 500 se mimo komunikační služby nedaří zbytné spotřebě, kde reportovala výsledky společnost Tesla (- 14 %).

Thermo Fisher Scientific (8,2 %) roste po kvartálním reportu. Mimo dobré čísla management uvedl, že společnost cítí oživení poptávky ve všech hlavních segmentech. Nejedná se přitom o pouhé doplňování zásob, ale i dodávání analytických přístrojů, jelikož divize Analytical Instruments vzrostla o 15 %. Tržby za minulý kvartál dosahují USD 11,99 mld. a společně se ziskem na akcii USD 6,03 překonávají očekávání trhu. Společnost rovněž navyšuje odhad celoročního zisku na akcii na horní hranu USD 25,33.

Smíšený pocit z kvartálních výsledků mají investoři Freeport-McMoRan (- 2,6 %). Společnost sice dosáhla na lepší ziskovost, než bylo očekávání a reportovala EPS ve výši USD 0,74. Meziroční nárůst prodejní ceny mědi dosáhl 40 %. Vyšší prodejní ceny tak kompenzují nižší objemy produkce, které u zlata dosahují 40 % a u mědi 18 %. Management snížil výhled prodeje v dalším kvartále kvůli pomalému obnovování těžby v indonéském dole, který by měl dosáhnout plnou kapacitu až v příštím roce.

Lockheed Martin (10 %) reportoval silné výsledky za uplynulý kvartál. Růst tržeb dosáhl 11 % na mld. 20,1 USD a zisk na akcii překonal na úrovni USD 7,94 očekávání. Management současně navýšil celoroční výhled a tržby posadil mezi USD 79,75 – 81,75 mld. při zisku na akcii 29,95 – 30,65. Nevyřízené zakázky dosahují historické maximum společnosti USD 230 mld.

Po včerejším uzavření trhu reportovala výsledky i společnost Texas Instruments (- 4,4 %). Růst tržeb meziročně dosáhl na 23 % a nad konsenzus se dostal i zisk na akcii ve výši USD 2,14. Management v dalším kvartálu očekává jeho další růst na USD 2,23 – 2,57. Provozní výsledky a výhled byl slušný, ale trh nadále vyrušuje výše capex investic, které omezuje volné cash flow.

Výsledky dále zveřejnila i IBM (- 0,5 %) a společnost Alphabet (- 6,6 %).

SK Hynix (4,9 %) stanovuje limit na celkový počet vydaných ADR, které se obchodují v USA na 2,5 % všech akcií společnosti.

Uber Technologies (- 2,15 %) propustil 10 % zaměstnanců v divizi Community Operations, která se stará o zákaznickou a řidičskou podporu. Společnost dříve propustila přibližně 23 % zaměstnanců HR. K zefektivnění provozu ji pomáhá umělá inteligence.

Blízký východ je nadále velmi turbulentní. Futures na ropu Brent jsou opět nad USD 100 při téměř 7 % růstu. WTI se obchoduje nad USD 92. Hútíové oznámili, že zaútočili na dva saúdské tankery v Rudém moři. Posilují ropné společnosti. Exxon připisuje 1,87 % a Chevron roste o 1,5 %.

Index S&P 500 -1,19 % na 7409,52 b. Nejsilnější sektory S&P Změna Nejslabší sektory S&P Změna Průmysl +1,8 % Zbytná spotřeba -4,9 % Energie +1 % Komunikační služby -4,8 % Zdravotní péče +0,8 % Nezbytná spotřeba -1,4 % Nejsilnější akcie S&P Změna Nejslabší akcie S&P Změna Allegion (ALLE) +13 % Tesla (TSLA) -14 % United Rentals (URI) +12 % Rollins (ROL) -9,3 % Lockheed Martin Corp (LMT) +10 % Dover Corp (DOV) -7,7 % Thermo Fisher Scientific (TMO) +8,2 % Globe Life (GL) -7,7 % RTX Corp (RTX) +7,2 % T-Mobile US (TMUS) -6,8 %
Marek Kameništiak
Fio banka, a.s.
Prohlášení

Key Takeaways TMO posted Q2 adjusted EPS of $6.03 and revenues of $11.99 billion, both above estimates.Thermo Fisher delivered 5% organic revenue growth with stronger customer activity across end markets.TMO expanded adjusted operating margin to 22.8% as profitability improved across all four segments. Thermo Fisher Scientific (TMO - Free Report) delivered second-quarter 2026 adjusted earnings of $6.03 per share, up 13% year over year. The figure beat the Zacks Consensus Estimate by 5.6%.

Revenues rose 10% to $11.99 billion and surpassed the consensus mark by 2.67%. Results were supported by 5% organic revenue growth, while customer activity strengthened across the company’s end markets.

Following the earnings announcement, TMO stock rose 4.4% in pre-market trading today.

TMO's Segmental Growth BroadensLife Sciences Solutions revenues increased 12.6% year over year to $2.82 billion. Segment income rose to $1.04 billion from $919 million, while the segment income margin expanded 20 basis points to 37%.

Laboratory Products and Biopharma Services remained the largest business, with revenues climbing 11.6% to $6.69 billion. Segment income increased to $936 million from $825 million, and margin improved to 14% from 13.8%. The segment accounted for 55.8% of consolidated revenues before eliminations.

Analytical Instruments revenues advanced 6.9% to $1.85 billion. Segment income jumped to $424 million from $325 million, driving margin expansion to 23% from 18.8%. The improvement made this segment the strongest margin gainer in the quarter.

Specialty Diagnostics revenues grew 6.3% to $1.21 billion. Segment income reached $334 million compared with $306 million a year earlier, while margin increased to 27.7% from 27%. Together, the two smaller segments added growth without diluting overall operating profitability.

TMO Expands Operating LeverageAdjusted operating income increased 15% year over year to $2.74 billion. The adjusted operating margin widened 90 basis points (bps) to 22.8%, reflecting stronger profitability across all four business segments.

On a GAAP basis, operating income rose 14% to $2.09 billion, while the operating margin improved 50 bps year over year. The cost of revenues was $7.05 billion, selling, general and administrative expenses were $1.91 billion, and research and development spending totaled $364 million.

Thermo Fisher’s Cash Deployment Reflects Strategic MovesThermo Fisher ended the second quarter with cash and cash equivalents of $4.06 billion compared with $3.25 billion at the end of the first quarter.

Cumulative net cash provided by operating activities came to $3.32 billion, compared with $2.12 billion in the year-ago period.

The company repurchased $1 billion of stock during the quarter and announced the divestiture of its microbiology business. For the first six months of 2026, acquisitions net of cash acquired totaled $8.87 billion, share repurchases reached $4 billion, and dividends paid amounted to $337 million.

Thermo Fisher Deepens Customer PartnershipsThermo Fisher opened its flagship U.S. Bioprocess Design Center in Plainville, MA. The site expands its network of collaborative innovation hubs intended to help pharma and biotech customers accelerate drug development and optimize manufacturing.

The company also announced a collaboration with Precision Health Research, Singapore, to support the PRECISE-SG100K population health study. The project will use Thermo Fisher's integrated proteomics capabilities, including Olink technology and the Orbitrap Astral mass spectrometry system.

Our TakeThermo Fisher ended the second quarter with both earnings and revenues beating respective estimates. Performance reflected the strength of the company’s proven growth strategy, strong execution and the power of the PPI Business System. Expansion of the adjusted operating margin in the quarter is also very promising.

During the quarter, Thermo Fisher launched a range of high-impact, innovative new products, including the next-generation Orbitrap mass spectrometry platforms with AI-driven analytics. It also introduced the Applied Biosystems PowerFlex Thermal Cycler to improve workflow flexibility, speed and reproducibility in molecular biology laboratories.

TMO’s Zacks Rank and Key PicksThermo Fisher currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) , Danaher (DHR - Free Report) and Elevance Health (ELV - Free Report) .

Intuitive Surgical, carrying a Zacks Rank #2 (Buy), reported second-quarter 2026 adjusted EPS of $2.80, which surpassed the Zacks Consensus Estimate by 12.9%. Revenues of $2.89 billion beat the Zacks Consensus Estimate by 3.1%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

ISRG has an earnings yield of 3.1% compared to the industry’s negative 3% yield. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 16.53%.

Danaher, carrying a Zacks Rank #2 at present, posted second-quarter 2026 adjusted EPS of $1.94, exceeding the Zacks Consensus Estimate by 5.44%. Revenues of $6.27 billion topped the Zacks Consensus Estimate by 2.88%.

DHR has an earnings yield of 4.7% compared to the industry’s 4.1% yield. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 5.65%.

Elevance Health, carrying a Zacks Rank #2 at present, posted second-quarter 2026 adjusted EPS of $7.45, exceeding the Zacks Consensus Estimate by 20.6%. Revenues of $49.8 billion outperformed the consensus mark by 0.8%.

ELV has an earnings yield of 6.9% compared to the industry’s 4.1% yield. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 5.65%.

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 27, 2026. Second Quarter Highlights Second quarter revenue grew 10% to $11.99 billion Second quarter GAAP diluted earnings per share (EPS) grew 9% to $4.68 Second quarter adjusted EPS grew 13% to $6.03 “We delivered outstanding performance in the second quarter, reflecting the strength of our proven growth strateg.

Posted by Defense World Staff on Jul 22nd, 2026

Acumen Wealth Advisors LLC cut its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 14.7% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,562 shares of the medical research company’s stock after selling 2,166 shares during the period. Thermo Fisher Scientific makes up 1.7% of Acumen Wealth Advisors LLC’s investment portfolio, making the stock its 17th biggest holding. Acumen Wealth Advisors LLC’s holdings in Thermo Fisher Scientific were worth $6,181,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. High Note Wealth LLC lifted its holdings in Thermo Fisher Scientific by 170.6% in the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after purchasing an additional 29 shares during the last quarter. Swiss RE Ltd. bought a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $28,000. Beacon Financial Strategies CORP acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth $29,000. Olistico Wealth LLC bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth $29,000. Finally, Birchwood Financial Partners Inc. bought a new position in Thermo Fisher Scientific in the 4th quarter worth $29,000. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Trading Down 0.7% Shares of TMO opened at $522.68 on Wednesday. The stock’s 50-day moving average price is $487.32 and its 200 day moving average price is $513.58. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. Thermo Fisher Scientific Inc. has a 12-month low of $405.15 and a 12-month high of $643.99. The firm has a market capitalization of $194.24 billion, a price-to-earnings ratio of 28.73, a P/E/G ratio of 2.33 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last announced its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, topping the consensus estimate of $5.25 by $0.19. The company had revenue of $11.01 billion for the quarter, compared to analyst estimates of $10.86 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.Thermo Fisher Scientific’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter last year, the firm earned $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, research analysts predict that Thermo Fisher Scientific Inc. will post 24.84 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be paid a $0.47 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.34%.

Wall Street Analysts Forecast Growth A number of equities research analysts have issued reports on TMO shares. Robert W. Baird decreased their price target on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating for the company in a report on Friday, April 24th. Wolfe Research initiated coverage on Thermo Fisher Scientific in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 price objective for the company. Jefferies Financial Group raised Thermo Fisher Scientific to a “strong-buy” rating in a report on Friday, April 24th. Evercore set a $570.00 price objective on Thermo Fisher Scientific in a research report on Monday, July 6th. Finally, Weiss Ratings raised shares of Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, July 14th. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $602.14.

Check Out Our Latest Report on Thermo Fisher Scientific

Insider Activity at Thermo Fisher Scientific In other news, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the transaction, the chief operating officer directly owned 25,051 shares of the company’s stock, valued at approximately $11,590,095.66. This trade represents a 1.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile (Free Report)

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Recommended Stories Five stocks we like better than Thermo Fisher Scientific Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAtlantic Union Bankshares Co. $AUB Shares Acquired by Bessemer Group Inc.

NEXT HEADLINE »Bank of New York Mellon Corp Reduces Holdings in Barrick Mining Corporation $B

Posted by Defense World Staff on Jul 21st, 2026

Andra AP fonden raised its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 1,411.9% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 57,814 shares of the medical research company’s stock after acquiring an additional 53,990 shares during the quarter. Andra AP fonden’s holdings in Thermo Fisher Scientific were worth $28,417,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the business. Legacy Wealth Managment LLC ID increased its holdings in Thermo Fisher Scientific by 78.6% during the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock worth $25,000 after buying an additional 22 shares during the last quarter. High Note Wealth LLC lifted its stake in Thermo Fisher Scientific by 170.6% in the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 29 shares during the last quarter. Swiss RE Ltd. bought a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at about $28,000. JPL Wealth Management LLC acquired a new position in shares of Thermo Fisher Scientific during the 3rd quarter worth about $28,000. Finally, Beacon Financial Strategies CORP bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at about $29,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Wall Street Analyst Weigh In TMO has been the topic of several research analyst reports. KeyCorp restated an “overweight” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Evercore set a $570.00 target price on Thermo Fisher Scientific in a report on Monday, July 6th. Morgan Stanley reaffirmed an “overweight” rating and set a $620.00 price target on shares of Thermo Fisher Scientific in a report on Monday, April 27th. Wells Fargo & Company reduced their price objective on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Finally, Wolfe Research assumed coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $602.14.

Get Our Latest Analysis on Thermo Fisher Scientific

Thermo Fisher Scientific Stock Down 1.2% TMO stock opened at $526.04 on Tuesday. Thermo Fisher Scientific Inc. has a fifty-two week low of $403.36 and a fifty-two week high of $643.99. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15. The stock has a market capitalization of $195.49 billion, a price-to-earnings ratio of 28.92, a PEG ratio of 2.36 and a beta of 0.87. The business’s fifty day moving average price is $486.05 and its two-hundred day moving average price is $513.98.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last released its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, beating the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The business had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $10.86 billion. During the same period in the prior year, the company posted $5.15 earnings per share. Thermo Fisher Scientific’s revenue was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 24.84 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.34%.

Insiders Place Their Bets In other news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the sale, the chief operating officer directly owned 25,051 shares in the company, valued at approximately $11,590,095.66. This represents a 1.57% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Company Profile (Free Report)

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Further Reading Five stocks we like better than Thermo Fisher Scientific The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAndra AP fonden Sells 130,514 Shares of Texas Instruments Incorporated $TXN

NEXT HEADLINE »Andra AP fonden Trims Stock Holdings in Medtronic PLC $MDT